LUC00100I1 - - Google Patents

Info

Publication number
LUC00100I1
LUC00100I1 LUC00100C LUC00100I1 LU C00100 I1 LUC00100 I1 LU C00100I1 LU C00100 C LUC00100 C LU C00100C LU C00100 I1 LUC00100 I1 LU C00100I1
Authority
LU
Luxembourg
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00100(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of LUC00100I1 publication Critical patent/LUC00100I1/fr
Publication of LUC00100I2 publication Critical patent/LUC00100I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU00100C 2002-03-13 2019-02-12 LUC00100I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36400702P 2002-03-13 2002-03-13
PCT/US2003/007864 WO2003077914A1 (fr) 2002-03-13 2003-03-13 Utilisation de derives de benzimidazole alkyles n3 en tant qu'inhibiteurs de mek

Publications (2)

Publication Number Publication Date
LUC00100I1 true LUC00100I1 (fr) 2019-02-13
LUC00100I2 LUC00100I2 (fr) 2020-01-23

Family

ID=28041856

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00100C LUC00100I2 (fr) 2002-03-13 2019-02-12

Country Status (35)

Country Link
US (11) US20030232869A1 (fr)
EP (5) EP2275102B1 (fr)
JP (4) JP4093966B2 (fr)
KR (3) KR100984613B1 (fr)
CN (4) CN101486682B (fr)
AR (3) AR038971A1 (fr)
AT (1) ATE449605T1 (fr)
AU (2) AU2003218157C1 (fr)
BE (1) BE2019C510I2 (fr)
BR (1) BR122018007328B8 (fr)
CA (1) CA2478374C (fr)
CL (2) CL2012002380A1 (fr)
CY (3) CY1109727T1 (fr)
DE (1) DE60330227D1 (fr)
DK (4) DK2275102T3 (fr)
DO (4) DOP2003000613A (fr)
ES (5) ES2549159T3 (fr)
HK (3) HK1070823A1 (fr)
HU (2) HUE025767T2 (fr)
IL (4) IL163995A0 (fr)
IS (4) IS2748B (fr)
LT (1) LTC1482932I2 (fr)
LU (1) LUC00100I2 (fr)
MX (1) MXPA04008893A (fr)
NL (1) NL300974I2 (fr)
NZ (1) NZ535158A (fr)
PA (1) PA8569301A1 (fr)
PL (5) PL230179B1 (fr)
PT (4) PT2275102E (fr)
SG (3) SG2013013339A (fr)
SI (4) SI2130537T1 (fr)
TW (3) TWI338685B (fr)
UA (1) UA77765C2 (fr)
WO (1) WO2003077914A1 (fr)
ZA (1) ZA200407220B (fr)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100984613B1 (ko) * 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US20060084682A1 (en) * 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
ES2324165T3 (es) * 2003-02-26 2009-07-31 Kowa Co., Ltd. Tratamiento de la dermatitis alergica de contacto.
WO2005009975A2 (fr) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazoles n-methyle-substitues
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
WO2005028447A1 (fr) 2003-09-22 2005-03-31 S*Bio Pte Ltd Derives de benzimidazole: preparation et compositions pharmaceutiques
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
MXPA06005657A (es) 2003-11-19 2006-08-23 Array Biopharma Inc Inhibidores heterociclicos de mek y metodos para usarlos.
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
NZ590160A (en) * 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
WO2006045514A1 (fr) 2004-10-20 2006-05-04 Applied Research Systems Ars Holding N.V. Derives de 3-arylamino pyridine
AU2005311451A1 (en) * 2004-12-01 2006-06-08 Merck Serono Sa [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
US7429667B2 (en) * 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
PL2364973T3 (pl) 2005-05-18 2014-12-31 Array Biopharma Inc Heterocykliczne inhibitory MEK i sposoby ich stosowania
KR20140000721A (ko) * 2005-06-23 2014-01-03 어레이 바이오파마 인크. 벤즈이미다졸 화합물의 제조 방법
KR101357361B1 (ko) * 2005-06-23 2014-02-03 아스트라제네카 아베 벤즈이미다졸 화합물의 ＳｎＡｒ 제조 방법
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
RS51782B (en) 2005-10-07 2011-12-31 Exelixis Inc. AZETIDINS AS MAK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AU2012261703B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
AU2013203939B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
US7968108B2 (en) * 2005-10-25 2011-06-28 Metbro Distributing L.P. Hydrogen cyanamide pesticide formulations
US7572460B2 (en) * 2005-10-25 2009-08-11 Rodrigo Rodriguez-Kabana Hydrogen cyanamide pesticide formulations
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
JP2009520780A (ja) * 2005-12-21 2009-05-28 アストラゼネカ アクチボラグ 癌の治療において有用なｍｅｋ阻害剤である６−（４−ブロモ−２−クロロフェニルアミノ）−７−フルオロ−ｎ−（２−ヒドロキシエトキシ）−３−メチル−３ｈ−ベンゾイミダゾール−５−カルボキシアミドのトシル酸塩
CA2534243A1 (fr) 2006-01-25 2007-07-25 Hydro Quebec Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
JP5269762B2 (ja) 2006-04-18 2013-08-21 アーディア・バイオサイエンシーズ・インコーポレイテッド Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
KR20150041164A (ko) 2006-07-06 2015-04-15 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 시클로펜타〔ｄ〕피리미딘
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
SI2054418T1 (sl) 2006-07-06 2012-02-29 Array Biopharma Inc Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
US8492378B2 (en) * 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
ZA200901009B (en) * 2006-08-21 2010-05-26 Genentech Inc Aza-benzothiophenyl compounds and methods of use
MX2009001878A (es) * 2006-08-21 2009-03-03 Genentech Inc Compuestos de aza-benzofuranilo y metodos de uso.
EP2069359B1 (fr) 2006-08-21 2014-11-12 Genentech, Inc. Composés aza-benzothiophényle et leurs procédés d'utilisation
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2008125820A1 (fr) * 2007-04-13 2008-10-23 Astrazeneca Ab Polythérapie comprenant de l'azd2171 et de l'azd6244 ou un inhibiteur de mek ii
US8509487B2 (en) * 2007-04-19 2013-08-13 Avago Technologies General Ip (Singapore) Pte. Ltd. System and method for optically measuring a parameter of an object
WO2008157179A2 (fr) 2007-06-12 2008-12-24 Genentech, Inc. Azaindoles n-substitués et procédés d'utilisation
BRPI0813993A2 (pt) 2007-07-05 2015-06-16 Array Biopharma Inc Ciclopentanos de pirimidila como inibidores de proteína quinase akt
CN101801955B (zh) 2007-07-05 2013-05-08 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CN101896180A (zh) * 2007-10-15 2010-11-24 阿斯利康(瑞典)有限公司 组合059
WO2009064675A1 (fr) 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Inhibiteurs de la mapk/erk kinase
PE20131210A1 (es) 2007-12-19 2013-10-31 Genentech Inc Derivados de 5-anilinoimidazopiridina como inhibidores de mek
ATE513832T1 (de) 2007-12-19 2011-07-15 Genentech Inc 8-anilinoimidazopyridine und ihre verwendung als antikrebsmittel und/oder entzündungshemmende mittel
WO2009080523A1 (fr) 2007-12-20 2009-07-02 F. Hoffmann-La Roche Ag Hydantoïnes substituées en tant qu'inhibiteurs de la mek kinase
AU2008340247B2 (en) 2007-12-21 2012-11-15 Genentech, Inc. Azaindolizines and methods of use
JP5539225B2 (ja) 2008-01-09 2014-07-02 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン
CA2711699A1 (fr) 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrimidylcyclopentanes hydroxyles utilises comme inhibiteurs de proteine kinase akt
EP2240494B1 (fr) 2008-01-21 2016-03-30 UCB Biopharma SPRL Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
WO2009157167A1 (fr) 2008-06-23 2009-12-30 パナソニック株式会社 Appareil de station de base de communication sans fil et procédé d'attribution de signal de référence
ES2426096T3 (es) 2008-07-01 2013-10-21 Genentech, Inc. Derivados de isoindolona como inhibidores de la quinasa MEK y métodos de utilización
CA2727250A1 (fr) 2008-07-01 2010-01-07 Genentech, Inc. Heterocycles bicycliques en tant qu'inhibiteurs de mek kinase
PE20110665A1 (es) 2008-08-04 2011-09-23 Merck Patent Gmbh Compuestos derivados de n-cichohexil-3-(fenilamino)-isonicotinamida como inhibidores de mek
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
US8470819B2 (en) * 2008-11-03 2013-06-25 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
JP5746630B2 (ja) 2008-11-10 2015-07-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換スルホンアミドフェノキシベンズアミド
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
JP2013508318A (ja) 2009-10-21 2013-03-07 バイエル・ファルマ・アクチェンゲゼルシャフト 置換されたベンゾスルホンアミド誘導体
WO2011047796A1 (fr) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Dérivés d'halogénophénoxybenzamide substitués
WO2011047795A1 (fr) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Benzosulfonamides substitués
WO2011095807A1 (fr) 2010-02-07 2011-08-11 Astrazeneca Ab Combinaisons d'inhibiteurs de mek et de hh
WO2011133520A1 (fr) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
KR20130048293A (ko) 2010-06-25 2013-05-09 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
CA2807510A1 (fr) 2010-08-05 2012-02-09 Case Western Reserve University Inhibiteurs de l'erk destines a traiter des troubles du developpement de la connectivite neuronale
SG188974A1 (en) 2010-10-06 2013-06-28 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
US9045429B2 (en) 2010-10-29 2015-06-02 Bayer Intellectual Property Gmbh Substituted phenoxypyridines
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
KR102482184B1 (ko) 2010-12-22 2022-12-28 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
US8815853B2 (en) 2010-12-23 2014-08-26 Sanofi Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
EP2694073B1 (fr) 2011-04-01 2018-08-08 Genentech, Inc. Combinaisons de inhibiteurs d'akt et mek pour le traitement du cancer
FI2694072T4 (fi) 2011-04-01 2024-09-30 Genentech Inc Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
WO2012145503A1 (fr) 2011-04-21 2012-10-26 Novartis Ag Combinaisons pharmaceutiques
EP2714039A1 (fr) * 2011-05-23 2014-04-09 Synta Pharmaceuticals Corp. Polythérapie de composés inhibiteurs de hsp90 avec inhibiteurs de mek
EP2714037B1 (fr) 2011-05-25 2016-07-13 Université Paris Descartes Inhibiteurs de la voie erk pour le traitement de l'amyotrophie spinale
EP3409278B8 (fr) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de protéine kinase hétérocycliques
KR20190133790A (ko) 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
MX2014002471A (es) * 2011-08-31 2014-03-27 Novartis Ag Combinaciones sinergicas de los inhibidores de p13k y mek.
BR112014002885A2 (pt) * 2011-09-01 2017-02-21 Novartis Ag uso de composto orgânico para o tratamento da síndrome de noonan
EP2570127A1 (fr) 2011-09-16 2013-03-20 Sanofi Compositions et procédés pour traiter le cancer avec un inhibiteur bêta PI3KB et un inhibiteur de la voie MAPK, incluant des inhibiteurs MEK et RAF
KR20200003245A (ko) 2011-10-14 2020-01-08 어레이 바이오파마 인크. 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
CA2853806C (fr) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Polytherapie d'inhibiteurs de hsp 90 avec des agents contenant du platine
EP2780010A1 (fr) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Association thérapeutique d'inhibiteurs de hsp90 et d'inhibiteurs de braf
RU2620068C2 (ru) 2011-11-23 2017-05-22 МЕДИММЬЮН, ЭлЭлСи Связывающие молекулы, специфичные по отношению к her3, и их применения
WO2013082511A1 (fr) 2011-12-02 2013-06-06 Genentech, Inc. Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
EP2802658A2 (fr) 2012-01-09 2014-11-19 Novartis AG Compositions organiques pour traiter des maladies associées à la bêta-caténine
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
CN103204825B (zh) 2012-01-17 2015-03-04 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
CA2868000C (fr) * 2012-03-20 2019-02-26 Novartis Pharma Ag Combinaison pharmaceutique renfermant un compose inhibiteur de mek et un anticorps anti-igfir destinee au traitement du cancer
WO2013152425A1 (fr) 2012-04-09 2013-10-17 Switch Materials , Inc. Matériaux de commutation, et compositions et procédés pour les fabriquer
JP6463673B2 (ja) 2012-05-29 2019-02-06 スイッチ マテリアルズ インコーポレイテッドＳｗｉｔｃｈ Ｍａｔｅｒｉａｌｓ Ｉｎｃ． 可変透過率層を含む光学フィルタ
MX2014014097A (es) 2012-05-31 2015-04-13 Bayer Pharma AG Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc).
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
SG11201500582UA (en) 2012-08-17 2015-04-29 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
ES2654143T3 (es) 2012-10-02 2018-02-12 Gilead Sciences, Inc. Inhibidores de desmetilasas de histonas
TR201807861T4 (tr) 2012-10-12 2018-06-21 Exelixis Inc Kanser tedavisinde kullanım için bileşikler yapmak için yeni işlem.
WO2014062838A2 (fr) 2012-10-16 2014-04-24 Tolero Pharmaceuticals, Inc. Modulateurs de pkm2 et procédés pour les utiliser
BR112015008623B1 (pt) * 2012-10-19 2022-10-25 Novartis Ag Processos de preparação de (2-hidroxietióxi)-amida do ácido 6-(4-bromo-2-fluorfenilamino) -7-flúor-3-metil-3h-benzoimidazol-5-carboxílico cristalizado e seus intermediários
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
UA115250C2 (uk) * 2012-11-29 2017-10-10 Новартіс Аг Фармацевтичні комбінації
WO2014097125A1 (fr) 2012-12-20 2014-06-26 Novartis Ag Combinaison pharmaceutique comprenant du binimétinib
EP2752191A1 (fr) 2013-01-07 2014-07-09 Sanofi Compositions et procédés utilisant un antagoniste de hdm2 et un inhibiteur de mek
CA2901747A1 (fr) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Production d'hepatocytes par programmation aller par genie genetique et chimique combine
AP2015008676A0 (en) 2013-02-27 2015-08-31 Epitherapeutics Aps Inhibitors of histone demethylases
WO2014133071A1 (fr) 2013-02-27 2014-09-04 第一三共株式会社 Procédé de prédiction de la réactivité à un composé inhibant la voie de transduction du signal de mapk
RU2019119893A (ru) 2013-03-14 2019-08-09 Толеро Фармасьютикалз, Инк. Ингибиторы jak2 и alk2 и способы их использования
DK2976106T3 (da) * 2013-03-21 2021-06-14 Array Biopharma Inc Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
WO2015041533A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
EP3049442A4 (fr) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
CN105829288B (zh) 2013-12-19 2019-01-15 爱杜西亚药品有限公司 抗菌1h-吲唑及1h-吲哚衍生物
WO2015108907A2 (fr) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour l'identification, l'évaluation, la prévention, et le traitement d'un mélanome à l'aide d'isoformes de pd-l1
CN104788365B (zh) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 异烟酰胺衍生物、其制备方法及应用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3604499A1 (fr) 2014-03-04 2020-02-05 Fate Therapeutics, Inc. Procédés améliorés de reprogrammation et plateformes de culture cellulaire
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
TWI697500B (zh) 2014-03-14 2020-07-01 瑞士商諾華公司 針對ｌａｇ-３之抗體分子及其用途
WO2015153498A1 (fr) 2014-03-31 2015-10-08 Epitherapeutics, Aps Inhibiteurs d'histones déméthylases
US20170107486A1 (en) 2014-04-21 2017-04-20 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
EA201692305A1 (ru) 2014-05-16 2017-05-31 Актелион Фармасьютиклз Лтд. Антибактериальные хиназолин-4(3н)-оновые производные
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
RU2733735C2 (ru) 2014-07-15 2020-10-06 Дженентек, Инк. Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов mek
MX2017002451A (es) 2014-08-27 2017-05-23 Gilead Sciences Inc Compuestos y metodos para inhibir histona desmetilasas.
AU2015314756A1 (en) 2014-09-13 2017-03-16 Novartis Ag Combination therapies of alk inhibitors
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
CA2969090C (fr) 2014-12-23 2023-05-02 Novartis Ag Composes triazolopyrimidine et leurs utilisations
WO2016123100A1 (fr) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Procédés et compositions pour induire la différenciation de cellules hématopoïétiques
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
CR20170410A (es) 2015-03-10 2017-11-08 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del "estimulador del gen interferon"
BR112017016817A2 (pt) 2015-03-25 2018-04-03 Novartis Ag derivados heterocíclicos formilados como inibidores de fgfr4
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
EP3964528A1 (fr) 2015-07-29 2022-03-09 Novartis AG Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
EP4378957A3 (fr) 2015-07-29 2024-08-07 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
EP4241850A3 (fr) 2015-08-28 2023-11-08 Novartis AG Inhibiteurs de mdm2 et combinaisons de ceux-ci
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
CA3004138A1 (fr) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Des anticorps se liant specifiquement a pd -1 et le tim -3 et leurs utilisations
AU2016348342B2 (en) 2015-11-04 2023-07-06 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
AU2016349504B2 (en) 2015-11-04 2023-02-09 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN108473959B (zh) 2016-01-20 2023-04-21 菲特治疗公司 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
US11413309B2 (en) 2016-01-20 2022-08-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
AU2017226389B2 (en) 2016-03-04 2023-02-02 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
EP3463345B1 (fr) 2016-06-03 2022-11-02 Array BioPharma Inc. Combinaisons pharmaceutiques
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
ES2798424T3 (es) 2016-06-20 2020-12-11 Novartis Ag Compuestos de triazolopiridina y usos de estos
ES2975263T3 (es) 2016-06-20 2024-07-04 Novartis Ag Formas cristalinas de un compuesto triazolopirimidínico
EP3507367A4 (fr) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
WO2018065924A1 (fr) * 2016-10-04 2018-04-12 Sun Pharmaceutical Industries Limited Intermédiaires d'inhibiteurs de la protéine kinase kinase activée par mitogène (map2k ou mek) et leur procédé de préparation
WO2018092064A1 (fr) 2016-11-18 2018-05-24 Novartis Ag Combinaisons d'inhibiteurs de mdm2 et d'inhibiteurs de bcl-xl
CN108084078B (zh) * 2016-11-24 2021-07-30 中山大学 一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
JP7098615B2 (ja) 2016-12-05 2022-07-11 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
EP3372624A1 (fr) 2017-03-06 2018-09-12 Henkel AG & Co. KGaA Composition à un composant à base de composés ayant au moins deux unités de carbonate cyclique exo-vinylène
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN109438362B (zh) * 2017-11-14 2020-07-21 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
CA3081602A1 (fr) 2017-11-16 2019-05-23 Novartis Ag Polytherapies
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
AU2019239404B2 (en) 2018-03-19 2021-12-23 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
CA3096984A1 (fr) 2018-04-05 2019-10-10 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de kinases axl et leur utilisation
KR20210015902A (ko) 2018-05-24 2021-02-10 얀센 바이오테크 인코포레이티드 Psma 결합제 및 이의 용도
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (fr) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Procédé de traitement de tumeurs neuroendocrines
BR112021001148A2 (pt) 2018-07-25 2021-04-20 Advanced Accelerator Applications S.A. soluções estáveis de complexo de radionuclídeo concentrado
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
MX2021001804A (es) 2018-08-17 2021-04-19 Novartis Ag Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
WO2020064693A1 (fr) 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Polythérapie
CN113473978A (zh) 2018-11-20 2021-10-01 恩福莱克逊治疗有限公司 用于治疗皮肤疾病氰基芳烃-苯胺化合物
US20240245670A1 (en) 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CA3127502A1 (fr) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprenant des inhibiteurs de proteine kinase heterocycliques
EP3924054A1 (fr) 2019-02-15 2021-12-22 Novartis AG Dérivés de 3-(1-oxo-5-(pipéridin-4-yl)isoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
KR20210141621A (ko) 2019-03-22 2021-11-23 스미토모 다이니폰 파마 온콜로지, 인크. Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
WO2020212832A1 (fr) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Procédé de préparation de composés de benzimidazole
KR20220002899A (ko) 2019-04-19 2022-01-07 얀센 바이오테크 인코포레이티드 항-psma/cd3 항체로 전립선암을 치료하는 방법
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CN114302878A (zh) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 酪氨酸激酶非受体1(tnk1)抑制剂及其用途
US20220280509A1 (en) 2019-09-26 2022-09-08 Novartis Ag Aza-quinoline compounds and uses thereof
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021116901A1 (fr) * 2019-12-09 2021-06-17 Biocon Limited Formes de binimétinib et procédé de préparation correspondant
WO2021123902A1 (fr) 2019-12-20 2021-06-24 Novartis Ag Combinaison d'anticorps anti-tim-3 mbg453 et d'anticorps anti-tgf-bêta nis793, avec ou sans décitabine ou l'anticorps anti pd-1 spartalizumab, pour le traitement de la myélofibrose et du syndrome myélodysplasique
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
EP4122925A4 (fr) * 2020-03-17 2024-04-17 Medshine Discovery Inc. Régulateur de protéolyse et son procédé d'utilisation
EP4134081A4 (fr) 2020-04-10 2024-05-01 Taiho Pharmaceutical Co., Ltd. Thérapie contre le cancer à l'aide d'un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de mek
AU2021289163B2 (en) 2020-06-09 2024-05-02 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
EP4204020A1 (fr) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Méthode de traitement de cancers exprimant le psma
EP4204021A1 (fr) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Méthode de traitement de cancers exprimant le psma
WO2022043556A1 (fr) 2020-08-31 2022-03-03 Novartis Ag Composition pharmaceutique stable
WO2022074011A1 (fr) 2020-10-05 2022-04-14 Pierre Fabre Medicament Association d'encorafénib et de binimétinib comme traitement adjuvant pour un mélanome de stade ii réséqué
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CN112679438A (zh) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 制备司美替尼的方法
CN112759552A (zh) * 2020-12-31 2021-05-07 武汉九州钰民医药科技有限公司 司美替尼的合成方法
AU2022210443A1 (en) * 2021-01-21 2023-09-07 Nflection Therapeutics, Inc. Processes for preparing pyrrolopyridine-aniline compounds
EP4284838A2 (fr) 2021-01-28 2023-12-06 Janssen Biotech, Inc. Protéines de liaison à psma et leurs utilisations
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
EP4308935A1 (fr) 2021-03-18 2024-01-24 Novartis AG Biomarqueurs pour le cancer et leurs méthodes d'utilisation
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4323356A1 (fr) 2021-04-13 2024-02-21 Nuvalent, Inc. Hétérocycles amino-substitués pour le traitement de cancers avec des mutations egfr
EP4322953A1 (fr) * 2021-04-15 2024-02-21 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de pkc et un inhibiteur de mek
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
KR102699226B1 (ko) 2021-06-09 2024-08-27 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
WO2022262699A1 (fr) * 2021-06-17 2022-12-22 深圳市塔吉瑞生物医药有限公司 Composé de benzimidazole substitué, composition le contenant et utilisation associée
JP2024529298A (ja) 2021-07-09 2024-08-06 プレキシウム インコーポレイテッド Ｉｋｚｆ２を調節するアリール化合物及び医薬組成物
AU2022383040A1 (en) 2021-11-04 2024-03-07 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer
WO2023084489A1 (fr) 2021-11-15 2023-05-19 Pfizer Inc. Procédés de traitement de la maladie à coronavirus 2019
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
WO2023225320A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées
WO2023225336A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de met bcl-xl et leurs procédés d'utilisation
WO2023238000A1 (fr) * 2022-06-06 2023-12-14 Glenmark Life Sciences Limited Procédé de préparation de sélumétinib et de sels de celui-ci
WO2024105144A1 (fr) 2022-11-18 2024-05-23 F. Hoffmann-La Roche Ag Composé de quinazolinone en tant qu'inhibiteur de braf pour le traitement d'un cancer solide avancé ou de métastases
WO2024189481A1 (fr) 2023-03-10 2024-09-19 Novartis Ag Conjugués anticorps-médicament inhibiteurs de panras et leurs procédés d'utilisation

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55501033A (fr) 1978-11-20 1980-11-27
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
US5218356A (en) * 1991-05-31 1993-06-08 Guenther Knapp Wireless indoor data relay system
US5216003A (en) * 1992-01-02 1993-06-01 G. D. Searle & Co. Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5750545A (en) 1993-07-23 1998-05-12 The Green Cross Corporation Triazole derivative and pharmaceutical use thereof
EP0639573A1 (fr) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
CZ104795A3 (en) 1994-04-29 1996-02-14 Lilly Co Eli Benzimidazole derivative, process of its preparation, its use for preparing a pharmaceutical preparation and the pharmaceutical composition containing thereof
US5520187A (en) * 1994-11-25 1996-05-28 General Electric Company Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
US5972980A (en) * 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
ES2183905T3 (es) 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
GB9600344D0 (en) * 1996-01-09 1996-03-13 Lilly Co Eli Benzimidzolyl neuropeptide y receptor antagonists
DE69712496T2 (de) 1996-07-18 2002-08-29 Pfizer Inc., New York Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
EP0950059B1 (fr) 1997-01-06 2004-08-04 Pfizer Inc. Derives de sulfone cyclique
ID22799A (id) 1997-02-03 1999-12-09 Pfizer Prod Inc Turunan-turunan asam arilsulfonilamino hidroksamat
BR9807824A (pt) 1997-02-07 2000-03-08 Pfizer Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
ID22809A (id) 1997-02-11 1999-12-09 Pfizer Turunan-turunan asam arilsulfonil hidroksamat
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
EP0993437B1 (fr) 1997-07-01 2006-11-08 Warner-Lambert Company Llc Derives d'acide benzoique 2-(4-bromo ou 4-iodo phenylamino) et utilisation de ces derniers en tant qu'inhibiteurs de mek
PT993439E (pt) 1997-07-01 2004-12-31 Warner Lambert Co Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US6534503B1 (en) * 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
WO2000040237A1 (fr) 1999-01-07 2000-07-13 Warner-Lambert Company Methode antivirale utilisant des inhibiteurs de mek
US6696440B1 (en) 1999-01-07 2004-02-24 Warner-Lambert Company Treatment of asthma with MEK inhibitors
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
CA2355374A1 (fr) 1999-01-13 2000-07-20 Warner-Lambert Company Diarylamines a substitution 1-heterocyclique
BR9916894A (pt) 1999-01-13 2001-11-20 Warner Lambert Co ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
EP1144371B1 (fr) 1999-01-13 2005-11-09 Warner-Lambert Company Llc Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek
WO2000042022A1 (fr) * 1999-01-13 2000-07-20 Warner-Lambert Company Les benzoheterocycles et leur utilisation comme inhibiteurs de mek
CA2348236A1 (fr) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
WO2001005390A2 (fr) 1999-07-16 2001-01-25 Warner-Lambert Company Methode de traitement de la douleur chronique au moyen d'inhibiteurs de mek
US7030119B1 (en) * 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
PL352712A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
JP2003504399A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
CN1373660A (zh) 1999-07-16 2002-10-09 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
WO2001021634A1 (fr) 1999-09-21 2001-03-29 Lion Bioscience Ag Derives de benzimidazole et bibliotheques combinatoires contenant ces derives
EP1339702A1 (fr) 2000-03-15 2003-09-03 Warner-Lambert Company Diarylamines a substitution 5-amide, utilises en tant qu'inhibiteur de kinases erk mitogenes mek
JP2003527379A (ja) 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
EA005818B1 (ru) * 2000-07-19 2005-06-30 Уорнер-Ламберт Компани Сложные эфиры фениламинобензгидроксамовых кислот
CA2420003A1 (fr) 2000-08-25 2002-03-07 Derick Dale Winkle Procede de fabrication d'acides n-aryle-anthraniliques et de leurs derives
AU2002210714A1 (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
WO2002046168A1 (fr) * 2000-12-07 2002-06-13 Astrazeneca Ab Composes therapeutiques de benzimidazole
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
JP4544820B2 (ja) * 2001-03-09 2010-09-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 複素環化合物
US20040039208A1 (en) 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
EP1427408A4 (fr) * 2001-09-17 2005-10-26 Bristol Myers Squibb Co Acides hydroxamiques cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace)
AU2002348791A1 (en) 2001-12-21 2003-07-09 Warner-Lambert Company Llc Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof
MXPA04005527A (es) 2002-01-23 2005-03-23 Warner Lambert Co ESTERES HIDROXIMATO DEL áCIDO N-(4-FENIL SUSTITUIDO)-ANTRANILICO.
KR100984613B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US20030216460A1 (en) * 2002-03-13 2003-11-20 Wallace Eli M. N3 alkylated benzimidazole derivatives as MEK inhibitors
DE10238002A1 (de) * 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
MXPA05002575A (es) * 2002-09-06 2005-09-08 Johnson & Johnson Compuestos heterociclicos.
US20040127395A1 (en) * 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
WO2005009975A2 (fr) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazoles n-methyle-substitues
DE102005032379A1 (de) 2005-07-08 2007-01-11 Conti Temic Microelectronic Gmbh Zugangskontrollsystem für ein Kraftfahrzeug
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
WO2014097125A1 (fr) 2012-12-20 2014-06-26 Novartis Ag Combinaison pharmaceutique comprenant du binimétinib

Also Published As

Publication number Publication date
DOP2013000023A (es) 2013-06-30
US20100267710A1 (en) 2010-10-21
ATE449605T1 (de) 2009-12-15
ES2335276T3 (es) 2010-03-24
DK3000810T3 (en) 2017-10-16
EP2275102B1 (fr) 2015-07-29
TWI343377B (en) 2011-06-11
SG194238A1 (en) 2013-11-29
US7425637B2 (en) 2008-09-16
TWI338685B (en) 2011-03-11
WO2003077914A1 (fr) 2003-09-25
US20110158971A1 (en) 2011-06-30
IL163995A (en) 2010-11-30
HUS1900011I1 (hu) 2019-04-29
US20100261718A1 (en) 2010-10-14
HK1141976A1 (en) 2010-11-26
DK2275102T3 (en) 2015-11-02
CA2478374A1 (fr) 2003-09-25
BE2019C510I2 (fr) 2022-05-19
IS8961A (is) 2011-06-16
DK1482932T3 (da) 2010-02-01
KR20100040760A (ko) 2010-04-20
KR100984573B1 (ko) 2010-09-30
PL401635A1 (pl) 2013-05-27
KR100984595B1 (ko) 2010-09-30
RU2307831C9 (ru) 2008-06-10
IL204420A0 (en) 2011-07-31
CN100519539C (zh) 2009-07-29
AU2009222613B2 (en) 2011-06-16
PL401637A1 (pl) 2013-05-27
EP1482932B1 (fr) 2009-11-25
US8513293B2 (en) 2013-08-20
BR122018007328B8 (pt) 2021-05-25
US7576114B2 (en) 2009-08-18
US20100267793A1 (en) 2010-10-21
CN101633645B (zh) 2011-06-22
JP2008163034A (ja) 2008-07-17
ES2394347T3 (es) 2013-01-30
ES2549159T3 (es) 2015-10-23
KR100984613B1 (ko) 2010-09-30
SI1482932T1 (sl) 2010-02-26
JP4093966B2 (ja) 2008-06-04
US20080171778A1 (en) 2008-07-17
IL204420A (en) 2012-12-31
US8193231B2 (en) 2012-06-05
CN101633644A (zh) 2010-01-27
CL2012002381A1 (es) 2012-11-05
KR20100040759A (ko) 2010-04-20
RU2004127926A (ru) 2005-06-27
PA8569301A1 (es) 2004-10-08
EP2130536A1 (fr) 2009-12-09
PT1482932E (pt) 2010-01-12
CN101633645A (zh) 2010-01-27
US8193229B2 (en) 2012-06-05
US7777050B2 (en) 2010-08-17
TW201031641A (en) 2010-09-01
US20080177082A1 (en) 2008-07-24
DOP2011000109A (es) 2011-11-30
SG148857A1 (en) 2009-01-29
US8003805B2 (en) 2011-08-23
IL204419A0 (en) 2011-07-31
CY2019012I2 (el) 2020-05-29
AU2003218157C1 (en) 2011-11-24
NZ535158A (en) 2007-06-29
LUC00100I2 (fr) 2020-01-23
IL204419A (en) 2012-12-31
PL230179B1 (pl) 2018-09-28
JP2008019277A (ja) 2008-01-31
KR20040094786A (ko) 2004-11-10
US20030232869A1 (en) 2003-12-18
SI2130537T1 (sl) 2013-01-31
EP2130536B1 (fr) 2013-05-08
DK2130537T3 (da) 2013-02-18
JP5498546B2 (ja) 2014-05-21
CY1109727T1 (el) 2014-09-10
CN1652776A (zh) 2005-08-10
CN101633644B (zh) 2012-05-09
PL401636A1 (pl) 2013-05-27
US20100261717A1 (en) 2010-10-14
CY1119136T1 (el) 2018-02-14
ES2407849T3 (es) 2013-06-14
DE60330227D1 (de) 2010-01-07
TWI350285B (en) 2011-10-11
PT2275102E (pt) 2015-10-27
EP2130537B1 (fr) 2012-11-14
AU2003218157A1 (en) 2003-09-29
ES2635666T3 (es) 2017-10-04
CN101486682B (zh) 2013-08-14
CY2019012I1 (el) 2020-05-29
SI2275102T1 (sl) 2015-12-31
AU2009222613A1 (en) 2009-10-29
RU2307831C2 (ru) 2007-10-10
PL233493B1 (pl) 2019-10-31
EP1482932A1 (fr) 2004-12-08
TW201031642A (en) 2010-09-01
US20100260714A1 (en) 2010-10-14
US7973170B2 (en) 2011-07-05
NL300974I2 (nl) 2022-04-06
CA2478374C (fr) 2009-01-06
JP5102642B2 (ja) 2012-12-19
CN101486682A (zh) 2009-07-22
DOP2003000613A (es) 2003-09-30
IS2998B (is) 2018-06-15
IL163995A0 (en) 2005-12-18
JP2005530709A (ja) 2005-10-13
DOP2011000110A (es) 2011-11-30
US8193230B2 (en) 2012-06-05
LTPA2019007I1 (lt) 2019-03-25
HK1153139A1 (zh) 2012-03-23
IS2999B (is) 2018-06-15
US8178693B2 (en) 2012-05-15
PL401638A1 (pl) 2013-05-27
SI3000810T1 (sl) 2017-10-30
BR122018007328B1 (pt) 2020-03-03
IS8960A (is) 2011-06-16
IS8959A (is) 2011-06-16
PT2130537E (pt) 2012-12-20
HUE025767T2 (en) 2016-05-30
US20050143438A1 (en) 2005-06-30
EP3000810A1 (fr) 2016-03-30
EP1482932A4 (fr) 2006-04-05
IS7442A (is) 2004-09-09
PL377628A1 (pl) 2006-02-06
US20120277277A1 (en) 2012-11-01
IS2990B (is) 2017-12-15
IS2748B (is) 2011-08-15
AR038971A1 (es) 2005-02-02
EP2275102A1 (fr) 2011-01-19
UA77765C2 (en) 2007-01-15
AU2003218157B2 (en) 2009-07-09
JP2012224649A (ja) 2012-11-15
HK1070823A1 (en) 2005-06-30
CL2012002380A1 (es) 2012-11-05
LTC1482932I2 (lt) 2020-04-27
PL233177B1 (pl) 2019-09-30
AR090144A2 (es) 2014-10-22
PT3000810T (pt) 2017-10-25
MXPA04008893A (es) 2005-06-20
EP2130537A1 (fr) 2009-12-09
EP3000810B1 (fr) 2017-07-19
AR090143A2 (es) 2014-10-22
ZA200407220B (en) 2007-05-30
TW200407129A (en) 2004-05-16
SG2013013339A (en) 2014-12-30

Similar Documents

Publication Publication Date Title
BE2019C547I2 (fr)
BE2019C510I2 (fr)
BE2018C021I2 (fr)
BE2017C049I2 (fr)
BE2017C005I2 (fr)
BE2016C069I2 (fr)
BE2016C040I2 (fr)
BE2016C013I2 (fr)
BE2018C018I2 (fr)
BE2016C002I2 (fr)
BE2015C078I2 (fr)
BE2015C017I2 (fr)
BE2014C053I2 (fr)
BE2013C025I2 (fr)
BE2015C069I2 (fr)
BE2011C038I2 (fr)
JP2003220137A5 (fr)
JP2002234056A5 (fr)
JP2003227307A5 (fr)
JP2003204944A5 (fr)
BRPI0215435A2 (fr)
JP2003225205A5 (fr)
JP2003255020A5 (fr)
JP2003229433A5 (fr)
JP2003199776A5 (fr)